![]() Verastem Oncology Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. | ![]() Tanvex BioPharma Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs. | ![]() Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. | ![]() Relay Therapeutics Relay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities. | ![]() Mirati Therapeutics Mirati Therapeutics is an oncology company that designs and develops targeted therapies to address the genetic drivers of cancer. | ![]() InxMed InxMed (应世生物) is a clinical-stage biotechnology company that develops individualized medicines. | |
Founding Date | Founding Date 2010 | Founding Date 2013 | Founding Date 1996 | Founding Date 2016 | Founding Date 2013 | Founding Date 2018 |
Type | Type Public | Type Public | Type Public | Type Public | Type Subsidiary | Type Private |
Tags | ||||||
Locations | Locations Needham, US HQ Walsrode, DE | Locations Taipei, TW HQ New Taipei, TW Irvine, US San Diego, US San Diego, US | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations Cambridge, US HQ | Locations San Diego, US HQ Zug, CH | Locations HQ |
Employees | Employees 7328% increase | Employees 13628% decrease | Employees 76,057 | Employees 2724% decrease | Employees 1347% decrease | Employees 16 |
Valuation ($) | Valuation ($) 144.9 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 958.5 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | ||||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) NT$61.4m (FY, 2023) | Revenue (est.) $54.1b (FY, 2023) | Revenue (est.) $25.5m (FY, 2023) | Revenue (est.) $12.4m (FY, 2022) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods NT$1.7m (FY, 2023) | Cost of goods $8.2b (FY, 2023) | Cost of goods N/A | Cost of goods $600k (FY, 2022) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit NT$61.6m (FY, 2023) | Gross profit $47.7b (FY, 2023) | Gross profit N/A | Gross profit $11.8m (FY, 2022) | Gross profit N/A |
Net income | Net income ($87.4m) (FY, 2023) | Net income (NT$2.1b) (FY, 2023) | Net income $9b (FY, 2023) | Net income ($342m) (FY, 2023) | Net income ($740.9m) (FY, 2022) | Net income N/A |
Operating ⚠ | ||||||
Phase I/II Trials Products | Phase I/II Trials Products 6 (FY, 2020) | Phase I/II Trials Products N/A | Phase I/II Trials Products 100 (FY, 2022) | Phase I/II Trials Products N/A | Phase I/II Trials Products N/A | Phase I/II Trials Products N/A |
Funding | ||||||
Total funding raised | Total funding raised $ 170m | Total funding raised $ 346.9m | Total funding raised $ 6.5m | Total funding raised $ 520m | Total funding raised N/A | Total funding raised $ 19m |
Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs.
View companyNovartis is a company that researches, develops, manufactures, and markets healthcare products.
View companyRelay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities.
View companyMirati Therapeutics is an oncology company that designs and develops targeted therapies to address the genetic drivers of cancer.
View company